Advertisement
Advertisement

RNAZ

RNAZ logo

TransCode Therapeutics Inc

3.83
USD
-2.49
-39.35%
Dec 18, 15:26 UTC -5
Closed
...

TransCode Therapeutics Inc Profile

About

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

Info & Links

CEO

Thomas A. Fitzgerald

Headquarters

6 Liberty Square, #2382
Boston, MA 02109, UNITED STATES

Auditor

WithumSmith+Brown, PC

Share holders

--

Employees

10

TransCode Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

66.14M

Enterprise Value

64.27M

Enterprise Value/EBITDA(ttm)

-4.55

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

2.35

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-649.03%

Return on Invested Capital(ttm)

-854.76%

Return on Assets(ttm)

-281.34%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-14.11M

Net Income Available to Common(ttm)

-14.93M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.55

52-Week Change

-98.73%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

17.27M

Dividend Yield

0.00%

Float4

671.00K

% Held by Insiders

3.60%

% Held by Institutions

0.00%

Balance Sheet

Total Cash(mrq)

1.88M

Total Cash Per Share(mrq)

0.11

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.58%

Quick Ratio(mrq)

1.58%

Book Value Per Share(mrq)

0.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.69

Free Cash Flow(ytd)

-10.21M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement